US EditionURGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class ...
- On June 6, 2025, Robbins LLP announced the filing of a class action lawsuit representing investors who bought or acquired shares of UroGen Pharma Ltd. Between late July 2023 and mid-May 2025.
- The action follows UroGen's submission of a rolling NDA for UGN-102 in August 2024 and subsequent FDA doubts about the drug's efficacy data.
- The FDA briefing on May 16, 2025, highlighted the absence of a simultaneous control group in the ENVISION study, which complicated the interpretation of key efficacy measures, and noted that randomized trials had been repeatedly suggested during the development process.
- Following the Oncological Drugs Advisory Committee’s May 21, 2025 vote against approval, UroGen’s stock fell 44.7%, reflecting concerns about UGN-102's unfavorable benefit-risk profile.
- The lawsuit alleges UroGen failed to disclose trial design flaws and risks of NDA rejection, potentially allowing investors to seek recovery without fees by July 28, 2025.
Insights by Ground AI
Does this summary seem wrong?
9 Articles
9 Articles
All
Left
1
Center
6
Right
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 6, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the "Class…
Hastings TribuneReposted by 
Enid News & Eagle
Enid News & EagleURGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class ...
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15,…
Globe NewswireReposted by 
dailyguardian.ca
dailyguardian.caURGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.
Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate ...
Coverage Details
Total News Sources9
Leaning Left1Leaning Right0Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage